343.1 Clinical utility of Donor-Derived cell-free DNA (ddcfDNA) in non-invasive monitoring of Liver transplant recipients
Dr. Naresh Shanmugam, India
343.2 Combination of SIRPa genotype in recipient and donor modulates immune response after living donor liver transplantation
Dr. Akhmet Seidakhmetov, Japan
343.3 Up-regulated LRRN2 expression is effective as a marker for graft quality in living donor liver transplantation
Dr. Takahiro Tomiyama, Japan
343.4 Changes of Glutathione excretion during normothermic machine perfusion of livers and potential influencing transplant factors
Dr. Christina Bogensperger, Austria
343.5 Hypothermic Oxygenated Machine Perfusion of the Liver via Hepatic Artery and Portal Vein Reduces Biliary Complications
Dr. David Pereyra, Austria
343.6 Long-term ex situ normothermic machine perfusion: Red-blood cell substitution enables preservation for one week with a fully automated NMP device
Dr. Julia Hofmann PhD, Austria
343.7 The association of hepatic artery resistive index and graft failure; Analysis of various cut-off values
Dr. Rozita Khodashahi, Iran
343.8 The short- and long-term outcomes of steroid-free regimen in liver transplantation
Dr. Kazuki Sasaki, Japan
343.9 Impact of donor hepatic duct bifurcation location and angle on post-transplant biliary complications in recipients following living donor liver transplantation